Genentech has accused the University of Pennsylvania of committing "patent fraud," reports The Daily Pennsylvanian's Laura Cofsky. The company is suing the school over a cancer treatment they both say is theirs, Cofsky says. Penn tested the treatment on transgenic mice engineered to develop cancer, and accused Genentech of patent infringement when the school noticed a patent from the company for the same treatment. Genentech then filed a counter complaint in May 2012, and is now suing, Cofsky says. "Furthermore, according to court documents, Genentech also believes Penn is misrepresenting its patent, alleging that Penn inaccurately reported both the life expectancy and final population size of their lab mouse test group," she adds. The company isn't asking for monetary damages, but for the court to declare Penn's patent invalid.
(HT: Pharmalot's Ed Silverman)